Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Impax gets exclusive US rights to AZ’s Zomig for migraine

Executive Summary

Impax Pharmaceuticals, the branded drugs division of Impax Laboratories Inc., has licensed exclusive US marketing rights to AstraZeneca PLC’s migraine therapy Zomig (zolmitriptan), in both the oral disintegrating tablet and nasal spray formulations.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Marketing (Licensing)
    • Reverse Licensing

Related Companies

UsernamePublicRestriction

Register